Ph ALL relapsed
Showing 1 - 25 of >10,000
Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- chidamide
- +2 more
- (no location specified)
Oct 19, 2023
Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)
Recruiting
- Acute Lymphoblastic Leukemia
- cladribine, cytarabine,venetoclax
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 22, 2022
Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)
No longer available
- Acute Lymphoblastic Leukemia (ALL)
- (no location specified)
Aug 5, 2022
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in
Not yet recruiting
- Lymphoblastic Leukemia, Acute, Childhood
- +3 more
- Olverembatinib, APG-2575, Dexamethasone
-
Hefei, Anhui, China
- +3 more
Aug 8, 2022
Lymphoma Leukemia Trial in Minneapolis (allogeneic CAR19 regulatory T cells (CAR19-tTreg))
Not yet recruiting
- Lymphoma Leukemia
- allogeneic CAR19 regulatory T cells (CAR19-tTreg)
- +2 more
-
Minneapolis, MinnesotaMasonic Cancer Center - University of Minnesota
Dec 6, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab
Not yet recruiting
- Ph+ ALL
- +2 more
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022
T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)
Recruiting
- T-lymphoblastic Lymphoma
- T-ALL
- CAR-T
-
Shanghai, ChinaShanghai Ruijin Hospital
Nov 14, 2023
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)
Completed
- Chronic Myelogenous Leukemia
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
-
Tokyo, JapanNovartis Investigative Site
Dec 6, 2020
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +7 more
- Blinatumomab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)
Completed
- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
-
Bordeaux, Aquitaine, France
- +11 more
Dec 6, 2020
Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib)
Not yet recruiting
- Philadelphia-Positive ALL
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Jul 1, 2023
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)
Recruiting
- CAR
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2022
Acute Lymphoblastic Leukemia, Adult Trial in Caba (Evaluation of survival and toxicities in AYA Ph-negative ALL patients
Recruiting
- Acute Lymphoblastic Leukemia, Adult
- Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
-
Paraná, Entre Ríos, Argentina
- +1 more
Dec 29, 2022
B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- HY004
- +2 more
- (no location specified)
Aug 18, 2023
B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)
Recruiting
- B Acute Lymphoblastic Leukemia
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022
Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed Trial in Czechia (Blinatumomab)
Active, not recruiting
- Lymphoblastic Leukemia, Acute, Adult
- +2 more
-
Brno, Czechia
- +4 more
Aug 3, 2022
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)
Not yet recruiting
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
- (no location specified)
Sep 25, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- QH103 Cell Injection
- +2 more
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Sep 21, 2023
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Olverembatinib
- +3 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Oct 21, 2022
Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)
Active, not recruiting
- Relapsed Adult ALL
- Relapsed Adult AML
-
Changchun, Jilin, ChinaFirst Hospital of Jilin University
Nov 19, 2023
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL),
Recruiting
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
- +2 more
- Ponatinib
- +2 more
-
Phoenix, Arizona
- +69 more
Aug 23, 2022